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bstract
An in vitro platform to perform peptide screening against different cancer cell lines was designed. The strategy for this screening
elied on the design and detection of high-affinity cancer-targeting peptides based on the sequences of NGR and P160. Evaluation of
he best binding peptides was performed via incubation of the peptide array-bounded cells with MTT reagent, which is reduced to
urple formazan in living cells and further quantified using an Elispot and Kodak imager. For proof of concept, a peptide library (132
pots, and 66 different peptides) was designed, synthesized, and screened against different cancer cell lines. The current strategy
ssists in the identification of positive and negative peptides as well as the relative binding between positive ones. Better binding
eptide sequences of the NGR motif were demonstrated to show up to a 2.6-fold increase in CD13+ cell lines with insignificant
inding to CD13− ones. Comparable results were observed for P160 peptide sequences, to which different peptides had increased
inding, with an up to 3-fold increase relative to the native P160 peptide. Based on our results, new peptide sequences for cancer
argeting were identified, and the developed strategy was applied to two different peptide libraries.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Taibah University. This is an open access article under
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cancer is one of the major health-related issues world-
wide [1]. Extensive efforts have been taken towards
cancer therapy and diagnosis. Traditional approaches to
locate, target and destroy tumour cells are limited by the
restricted access to tumours, unwanted effects, and non-thesis, and validation of an in vitro platform peptide-whole
), http://dx.doi.org/10.1016/j.jtusci.2016.10.001
behalf of Taibah University. This is an open access article under the
selectivity to tumour cells [1]. To improve the outcomes
of available cancer therapies, targeting chemotherapy
drugs seems to be a good option [2,3]. Molecularly
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targeted therapy has become a reality in the treatment of
cancers. Rituxan, an anti-CD-20 monoclonal antibody,
is being used to treat B-cell lymphoma [4,5]. Herceptin,
an anti-Her2/neu monoclonal antibody, is in clinical use
to treat breast cancer [6]. Most recently, STI-571, an
inhibitor of BCR-ABL and KIT tyrosine kinases, is being
used to treat chronic myeloid leukaemia [7] and gas-
trointestinal stromal tumour [8]. Efforts are continuing
to identify additional cellular targets for new anticancer
therapy as well as to increase the target specificity of
various drugs or use them as diagnostic agents for can-
cer tissue [9–13]. Recently, different peptides have been
recognized by peptide phage display for targeting dif-
ferent tumours and cell types [9,14–16]. Among these,
RGD contains peptides that home to v3 and v5 inte-
grins [2,17,18]. A second peptide motif has the general
structure of CX3CX3CX3C (X = different amino acids,
C = cysteine). An aminopeptidase N (CD13) targeting
peptide has an NGR adhesion motif [19–22] that binds
a specific aminopeptidase N isoform in tumour vessels,
but not to other isoforms expressed in normal epithelia
[22,23]. Coupling of CNGRC peptides to different anti-
cancer compounds has been shown to enable targeted
delivery of these drugs to tumour vessels [2,24,25]. In
addition to CNGRC, other linear NGRAHA and cyclic
CVLNGRMEC peptides were identified [21]. Differ-
ent linear and cyclized NGR peptides are useful for
delivering anti-tumour drugs, and cyclized peptides have
superior action. The improved targeting of cyclized pep-
tides could be due to the stabilized bent conformation
obtained through the cyclization that is required for bet-
ter binding to the receptor [19]. A dodecapeptide peptide,
p160, with affinity to neuroblastoma and breast cancer
cell lines, has also been identified through phage display
[16,26,27]. A virus capsid that was decorated with the
P160 peptide on its surface showed tumour in vivo target-
ing [28]. The choice of a targeting vehicle is determined
by its selective binding to a tumour and limited uptake
by healthy tissues [28]. Several peptides have been iden-
tified through the use of the phage display technique.
However, these peptides cannot be further improved to
achieve better stability and selectivity through the use
of unnatural amino acids or by chemical manipulation
of their structures with the same technique [25]. Such
an approach would be more flexible using autospot for
the synthesis of peptide arrays based on the strategy
developed by Ronald Frank [29,30]. Previously designed
peptide arrays serve as tools for profiling enzymaticPlease cite this article in press as: S. Ahmed, K. Kaur. Design, syn
cell screening assay using MTT reagent, J. Taibah Univ. Sci. (2016
kinase activity in cellular lysates; however, this tech-
nique requires extensive validation [31].
We have previously shown that peptide array-whole
cell binding technique permits rapid synthesis and high PRESS
rsity for Science xxx (2016) xxx–xxx
throughput screening of a large number of peptides with
various structures and conformations because of their
ability to bind to unique target proteins on the cancer
cell surface [30]. Using this technique, our lab was able
to identify several important ligands against different
tumour cell surface receptors; these include YNGRT
and CVLNGRSEC as NGR modified sequences [32]
as well as WXEAAYQRFL and RGDPAYQGRFL as
modified sequences for the p160 peptide [30]. Peptide
array-whole cell binding seems to be a good complemen-
tary method to phage display to identify better binding
peptides through the incorporation of natural and unnat-
ural amino acids [30,32].
The general objective of our current study was to
develop a peptide array-whole cell binding assay to
screen two different peptide libraries of interest by
the use of a colour detection method compared to a
previously described fluorescence method [30,32]. Our
libraries that were synthesized on a cellulose mem-
brane were based on two different peptide sequences.
One library was based on the sequence of cyclic CVL-
NGRMEC peptides to specifically target cancer cells
expressing CD13 receptors. The second library was
based on the p160 sequences to specifically target breast
cancer. Using these peptide libraries, we developed an
easy, sensitive and reliable assay for screening NGR and
P160 peptides using MTT reagent and both Elispot and
Kodak imager as screening techniques.
2.  Results  and  discussion
Engineering peptide sequences allows for a better
selection of sequences that best bind to cell surface
receptors. Using immobilized synthetic peptides on the
surface of a cellulose membrane would enable evalua-
tion of such an interaction. Applying this strategy, we
were able to identify better binding sequences as well
as confirm results that were previously obtained with
other detection methods. We previously showed that
peptide arrays on cellulose membranes are excellent plat-
forms for screening a large number of peptides against
whole cells to investigate their selective binding affinity
[30,32]. In our previous work, we used fluorescence to
detect the binding affinity of the tested peptides to dif-
ferent cell lines with CyQuant dye. In the current study,
we tried to use the colour detection method. The peptide
array was incubated with specific cancer cell lines of
interest. Nonspecific binding was removed by washing,thesis, and validation of an in vitro platform peptide-whole
), http://dx.doi.org/10.1016/j.jtusci.2016.10.001
and the bound cells were labelled with the MTT reagent.
Inside living cells, the yellow colour of MTT (3-(4,4-
Dimethlthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
is reduced to dark violet formazan, which is largely
ARTICLE IN PRESS+ModelJTUSCI-340; No. of Pages 10
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F MTT reagent inside the mitochondria to a violet colour with images obtained
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Fig. 2. Expression level of aminopeptidase N (APN; CD13): the level
of CD13 in HT-1080 and MDA-MB-231 cells was analyzed by flow
cytometry after incubating each cell line with a FITC-labelled mono-ig. 1. Illustration of the detection method: chemical modification of 
rom both a Kodak Imager and ElisSpot Bioreader.
mpermeable to cell membranes. This reduction occurs
hrough the action of mitochondrial reductase enzyme,
s shown in Fig. 1 [33]. Researchers in immunology use
he Elispot technique as a tool for detecting the levels of
ytokines, chemokines, and enzymes that are produced
y cells under certain conditions to help to highlight indi-
idual cells [34,35]. Detection occurs by measuring the
nsoluble produced colour. Therefore, we thought about
sing the same approach as a tool to detect the bind-
ng level of the cell of interest to the covalently attached
eptides by incubating the cells with MTT reagent. The
olour produced can be detected at 535 nm by either
n Elispot or Kodak imager, and quantitative estimation
f the colour intensity was measured with the Kodak
mager. The relative cell adhesion (RCA) of the peptides
as estimated based on the intensity of the dark violet
olour produced by the bound cells and was calculated
elative to the value obtained by the lead peptide.
.1.  NGR  peptide  library
.1.1.  Aminopeptidase  N  (CD13)  expression
The specific level of aminopeptidase N (CD13)
xpression was assessed in two different cell lines,
T-1080 (human fibrosarcoma) and MDA-MB-231
reast cancer cells. A high binding affinity for the
ITC-labelled antihuman CD13 antibody (WM15) was
bserved for the HT-1080 cell lines, which are APN
CD13) positive with a mean fluorescence intensity
f approximately 51 (Fig. 2), while MDA-MB-231Please cite this article in press as: S. Ahmed, K. Kaur. Design, syn
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ells, which are APN (CD13) negative, showed only
pproximately 6% expression. These results matched the
reviously reported CD13 expression levels of different
ell lines [36].clonal antihuman CD13 antibody (WM15) for 30 min at 4 ◦C. The
mean fluorescence intensity of three repeats for each cell type is shown.
2.1.2.  NGR  Peptide  Library  Design
Thirty different peptide sequences that contain the
NGR motif based on the lead peptide 1 (CVLNGRMEC)
were designed to study selective binding to CD13-
expressing cancer cell lines, HT-1080, (Table 1) at
∼50 nmoles and a distance of 4 mm. Methionine (Met)
was replaced in all of the designed sequences with
norleucine (Nle) to overcome oxidation during synthe-
sis and handling of the membrane. Previous studies
showed that the NGR motif is essential for binding to
the CD13 receptor in cancer cells expressing these recep-
tors [21]. The NGR motif was kept in all of the peptides
and only removed from the negative control peptidesthesis, and validation of an in vitro platform peptide-whole
), http://dx.doi.org/10.1016/j.jtusci.2016.10.001
(26–30). Peptides 3–7  represent an Ala scan of peptide
2, which has the same sequence as peptide 1, except
Met was replaced with Nle. Peptides 8–14  represent
ARTICLE IN+ModelJTUSCI-340; No. of Pages 10
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Table 1
Cell adhesion capacity of the NGR sequence-based library.a
Peptide # Peptide sequences Relative cell
adhesion HT-1080
1 CVLNGRMECZ 1.00
2 CVLNGRXECZ 1.71
3 CALNGRXECZ 1.62
4 CVANGRXECZ 1.20
5 CVLNGRAECZ 0.98
6 CVLNGRXACZ 1.16
7 CVLNGRXEAZ 0.96
8 CVLNGRXCZ 0.86
9 CVLNGRCZ 1.10
10 CVLNGRECZ 0.50
11 CLNGRXECZ 0.70
12 CVNGRXECZ 0.62
13 CNGRXECZ 1.30
14 CNGRCZ 2.60
15 CVLNGRXDCZ 2.60
16 CZLNGRXECZ 1.10
17 CNGRGECZ 1.40
18 CNGRGXCZ 1.40
19 CVLNGRGECZ 0.94
20 CVZNGRXECZ 0.97
21 CLNGRXCZ 0.81
22 CNGRGEQCZ 1.00
23 CNGRGENCZ 1.30
24 CQGRGEQCZ 0.12
25 CVLQGRXECZ 1.34
26 CVLARAXECZ 1.04
27 CARACZ 0.48
28 AVLXGXEAZ 0.00
29 VLGXEZ 0.03
30 CVLGXECZ 0.76
a The C-terminus of the peptides is covalently attached to the cellu-
lose membrane through an amidic bond, the N-terminal is acetylated.
An amino acid replacement or insertion of an amino acid in the NGR
sequence is underlined. X stands for norleucine. The relative cell adhe-
sion is the average ratio of the intensity of a peptide divided by the lead
peptide CVLNGRMEC.
NGR-truncated peptides, where either N- or C-terminal
amino acids were removed. Peptide 15  has an Asp instead
of Glu8 to study the effect of the side chain length; the
same strategy was applied for peptides 22–25, where Asn
was replaced with Gln at different sites. Peptides 16  and
20 had -ala instead of Val2 or Leu3, respectively. For
peptides 17–19, Nle was replaced with Gly to study the
effect of hydrophobicity reduction. The remaining pep-
tides were essentially scrambled sequences that lacked
the NGR motif and had varying lengths.
2.1.3. Peptide  array-whole  cell  binding  assay  usingPlease cite this article in press as: S. Ahmed, K. Kaur. Design, syn
cell screening assay using MTT reagent, J. Taibah Univ. Sci. (2016
MTT reagent
The affinity of the NGR peptides for the two can-
cer cell lines (HT-1080 and MD-MB-231) was studied PRESS
rsity for Science xxx (2016) xxx–xxx
using MTT reagent as a detection tool and visualized
using both Kodak imager and Elispot bioreader. From the
binding experiment of the cellulose-bound peptides and
cancer cell lines, a high binding affinity was observed
for HT-1080 cells (CD13+) compared to MD-MB-231
cells (CD13−). The relative cell adhesion (RCA) ratio for
each peptide was calculated for CD13+ cells (Table 1).
First, replacement of Met with Nle increases the bind-
ing of the peptide to cells, which might be due to the
stabilization of the peptides. From the Ala-scan of pep-
tide 2, only peptide 3, for which Val was replaced with
Ala, was able to maintain the same binding as peptide
2, which is in agreement with the results of Honda and
coworkers, as they showed that this type of replacement
had a high cell adhesion effect and induced cell-specific
interactions [37]. Deletion of amino acids from either
the C- or N-terminus reduces the binding affinity com-
pared to peptide 2  (Table 1). The validity of our strategy
was further proofed by the identification of peptide 14
among the various tested peptides with NGR that were
more efficient than other linear forms [19]. This peptide
has also been widely used as a CD13 tumour vascul-
ature targeting peptide; for instance, tumour necrosis
factor- (TNF) conjugated to this peptide is now in
phase II clinical trials [2,22]. Its capability for higher
binding might result from the well-constrained struc-
ture, which is well fit to a similar sequence GNGRG that
is found in the fibronectin sequence. Similarly, peptide
15, where Glu8 was replaced with Asp, showed higher
binding than peptide 2, which supported our previous
finding [32]. This high binding might reflect the impor-
tance of the side chain length to the binding affinity for
the CD13 receptor. Removal of the NGR motif from
the tested peptides (24–30) greatly reduced binding,
except for peptides 25  and 26, which showed enhanced
binding, which was also observed in our previous
work.
Binding of the designed peptides to MDA-MB-231
(CD13−) after regeneration of the membrane is shown in
Fig. 3. MDA-MB-231 cell lines express very low levels
of CD13 receptor, ∼6%, as shown from FACS analysis
(Fig. 2). MDA-MB-231 bound to the NGR peptide array
displayed very low binding, which is consistent with the
level of CD13 expressed on the cell surface. However,
this binding could also be correlated to the expression
of v3 integrins due to the conversion of NGR to the
isoRGD form [38]. Recently, our findings supported that
NGR-containing ligands can undergo a non-enzymatic
spontaneous deamidation of the asparagine (N) residuethesis, and validation of an in vitro platform peptide-whole
), http://dx.doi.org/10.1016/j.jtusci.2016.10.001
and form isoaspartate (isoRGD), which can bind to v3
and 51 integrins and contribute to detectable binding
[32,38].
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Fig. 3. Average colour intensity of the NGR peptide library bound to HT-10
MTT reagent, as obtained from the Kodak imager @535 nm. The results are p
Fig. 4. Spotscan image of HT-1080 cells bound to the NGR peptide
library taken by Elispot (A), HT-1080 cells bound to the NGR peptide
library taken by the Kodak imager (B), and MDA-MB-231 cells taken
b
o
K
r
o
full-length peptides makes a difference. In all of they the Kodak imager (C).
Visual detection of the binding of MTT-labelled cells
n different tested peptides was evaluated using both aPlease cite this article in press as: S. Ahmed, K. Kaur. Design, syn
cell screening assay using MTT reagent, J. Taibah Univ. Sci. (2016
odak and Elispot imager, which gave very cohesive
esults (Fig. 4). The differences in the binding affinity
f each peptide can be easily detected by the naked eye.80 (CD13+) and MDA-MB-231 (CD13−) cells after treatment with
resented as the mean intensity ± SD.
All of our analogues, including those with multiple dele-
tions, were maintained in cyclic forms within through the
disulfide bond, except two of the negative control pep-
tides. We found that keeping all of the critical amino
acids for NGR as well as cyclization was essential to
improv the affinity (Table 1), which is probably due to the
specific conformation required for receptor binding and
activation. To further confirm the validity of our results,
selected peptide spots (CNGRC;A, CALNGRXECZ;B,
CVNGRXECZ;C, and VLGXEZ;D) were reevaluated
for their binding to HT-1080 using CyQUANT dye, and
very cohesive results were obtained, as shown in Fig. 5.
2.2.  P160  peptide  library  design
Thirty-six peptides based on the p160 sequence
(VPWMEPAYQRFL) were designed for selective bind-
ing to different cancer cells lines, as shown in Table 2.
Previous studies have demonstrated that the N-terminal
Val and Pro residues do not play a role in binding, par-
ticularly in neuroblastoma WAC2 cell lines [26]. We
previously engineered a library of the p160 peptide based
on the sequence of WMEPAYQRFL [30]. Here, we
design and synthesize a new library based on the full
length of the peptides that were previously identified
by Zhang and coworkers (peptide 3), which were pre-
viously studied in WAC2 cell lines [16]. In our library,
MDA-MB-435 cells were used to better investigate the
entire length of the peptide and observe whether usingthesis, and validation of an in vitro platform peptide-whole
), http://dx.doi.org/10.1016/j.jtusci.2016.10.001
designed sequences, Nle was used instead of Met. In
peptide 2, Ala was replaced by -Ala, as it was pre-
viously shown by Askoxylakis and coworkers that this
ARTICLE IN PRESS+ModelJTUSCI-340; No. of Pages 10
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Top: usFig. 5. Spotscan of selected peptides bond to the HT-1080 cell lines. 
CyQuant dye and scanned with fluorescence microscopy.
replacement enhances binding to cancer cells [26]. Pep-
tides 4–14  represent Ala scanning of peptide 1. Peptides
15–18 represent truncated N-and C-terminal peptides.
For peptide 19, Glu5 was replaced by Asp; in peptide 7,
Gln9 was replaced by Asn to determine if the functional
group of the amino acid side chain and/or the length is
important. The effect of P160 cyclization on binding was
studied by placing two cysteines at the C- and N-termini,
as shown in peptide 21. Similarly, peptides 22–28  repre-
sent truncated as well as modified sequences; peptide 25
was previously reported by Askoxylakis and showed a
high reduction in binding to WAC 2 cells. Similarly, pep-
tide 26  has the same sequence as peptide 25, with Met4
replaced by Nle. In peptide 29, the site of the positive and
negatively charged amino acid was exchanged between
the N- and C-termini. In peptide 30, the sequence was
modified to increase the hydrophobicity. In peptides
31–32, six Asp amino acids were introduced into the
sequence to study both the effect of the negative charge
as well as increase the hydrophilic characteristics of the
binding. As a control, peptide 33  represents 8 amino
acids from the N-terminus of the Leucocine antimicro-
bial peptide plus Val  and Pro  from the N-terminus and
Phe and Leu  from the C-terminus of P160. Peptide 34
represents the amino acid sequence of octreotide, “syn-
thetic somatostatin analogue”, which has demonstrated
inhibitory activity against human breast cancer cells in
culture as a positive control [39]. Peptides 35  and 36  havePlease cite this article in press as: S. Ahmed, K. Kaur. Design, syn
cell screening assay using MTT reagent, J. Taibah Univ. Sci. (2016
the same sequence as peptides 3 and 2  to study if the posi-
tion of the peptide sequence can affect the accuracy of
the results.ing MTT reagent and scanned with the Elispot reader. Bottom: using
2.2.1.  P160  peptide  array-whole  cell  binding  assay
using MTT  reagent
From the membrane scan, some of the residues were
found to boost binding, such as for replacement of Ala
with -Ala as well as replacement of Gln with Asn.
Unexpectedly, we observed that when a few aspartic acid
residues were introduced, there was enhanced binding,
as seen for peptides 31  and 32.
The relative cell adhesion (RCA) of each peptide was
calculated based on the intensity of the formazan colour
produced relative to lead peptide 3 using the Kodak
Imager, as shown in Fig. 6 and Table 2. Very little bind-
ing of synthesized peptides was observed for the normal
HUVEC cell line compared to the MBA-MB-435 cancer
cell line (Fig. 6). As seen from Table 2, peptides 1  and 2
showed an enhanced binding affinity for MDA-MB-435,
which supported previous observations by our group and
others [26,30]. From the Ala-scanning peptides (4–14),
peptide 12  displayed the highest affinity in this group
relative to peptide 3, with an RCA of 1.84, where Arg10
was replaced by Ala. A slight reduction in the binding
affinity was observed for peptides 10  and 14  in which Ala
replaced Tyr8  and Leu12, respectively. In the truncated
peptides 15–18, removal of Phe11  and Leu12  reduced
the binding affinity, which supported a previous finding
[27]. Replacement of some N- or C-terminal residues
resulted in enhanced binding to MD-MB-435 cells. For
example, peptide 19, in which Glu5  was replaced withthesis, and validation of an in vitro platform peptide-whole
), http://dx.doi.org/10.1016/j.jtusci.2016.10.001
Asp, had improved cancer cell binding, with an RCA of
2.16, which might indicate the effect of the side chain
length on the interaction. A similar strategy was applied
ARTICLE IN+ModelJTUSCI-340; No. of Pages 10
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Table 2
Amino acid sequence and cell adhesion capacity of the P160 peptide
based peptide array library.a
Peptide # Peptide sequence Relative cell
adhesion (RCA)
MDA-MB -435
1 VPWXEPAYQRFLZ 1.47
2 VPWXEPZYQRFLZ 1.90
3 VPWMEPAYQRFLZ 1.00
4 APWXEPAYQRFLZ 0.88
5 VAWXEPAYQRFLZ 1.39
6 VPAXEPAYQRFLZ 1.25
7 VPWAEPAYQRFLZ 1.79
8 VPWXAPAYQRFLZ 1.03
9 VPWXEAAYQRFLZ 1.26
10 VPWXEPAAQRFLZ 0.99
11 VPWXEPAYARFLZ 1.63
12 VPWXEPAYQAFLZ 1.84
13 VPWXEPAYQRALZ 1.26
14 VPWXEPAYQRFAZ 0.81
15 PWXEPAYQFZ 1.09
16 WXEPAYQRFLZ 1.24
17 XEPAYQRFLZ 0.74
18 VPWMEPAYQRZ 0.73
19 VPWXDPAYQRFLZ 2.16
20 VPWXEPAYNRFLZ 1.65
21 CPWXEPAYQRFCZ 1.26
22 PWXDPAYQRZ 0.01
23 WXEPAYNRZ 0.65
24 VPWXEPAYQRZ 1.00
25 VPWMEPAYZ 0.12
26 VPWXEPAYZ 0.44
27 PWXEPAYZ 0.24
28 VPWXFLZ 1.41
29 VPWXRPAFADFLZ 1.70
30 VPWXANGGNGFLZ 1.89
31 VPWXDDDDDDFLZ 3.40
32 VPWXDDDDDDAAZ 2.00
33 KYYGNGVHVPFLZ 1.15
34 FCFWKTCTZ 1.60
35 VPWMEPAYQRFLZ 1.29
36 VPWXEPZYQRFLZ 2.16
a The C-terminus of the peptides is covalently attached to the cel-
lulose membrane through an amidic bond, and the N-terminus is
acetylated. Modified residues are colored and underlined. The RCA
i
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as the average ratio of the intensity of a peptide divided by the lead
eptide VPWMEPAYQRFL.
or peptide 20, where Gln9  was replaced with Asn, and
nhanced activity was observed, with an RCA of 1.65.
eplacement of Val1  and Leu12  with Cys  to produce
eptide 21  led to a minor improvement in RCA (1.26).
eptides 22–27  represent a negative control in which
he essential amino acids in the C- and N- termini arePlease cite this article in press as: S. Ahmed, K. Kaur. Design, syn
cell screening assay using MTT reagent, J. Taibah Univ. Sci. (2016
emoved and a significant reduction in the RCA value
as observed, except in the case of peptide 24, for which
he minimum sequence was identified by Askoxylakis
nd coworkers; in our experiment, it showed an RCA of PRESS
rsity for Science xxx (2016) xxx–xxx 7
1. Peptide 29  also has zero charges, as P160 had Arg near
the N-terminus exchanged with Asp near the c-terminus;
this exchange in the charge position seems to improve
the RCA (1.7). Interestingly an increase in the negative
charge on the peptide sequences, as in peptides 31  and 32,
greatly enhances the RCA, which cannot be explained,
but may be due to non-selective binding to cancer cell
lines. Peptide 33, which resembles the sequence of C-
terminal leucocine, showed improved binding, which
requires further investigation. Peptide 34  has the amino
acid sequence of octreotide and showed good binding
to MDA-MB-435. Peptides 35  and 36, which have the
same sequences as peptides 2  and 3, showed the same
relative enhancement of RCA. A very similar picture was
obtained from the Elispot scan via a qualitative approach.
In both methods of detection, eight promising peptides
were detected, and these are highlighted in red in Table 2.
2.2.2. Afﬁnity  of  selected  P160  peptides
Three selected peptides, 2, 3  (P160), and 19, were
further investigated using flow cytometry (Fig. 7) to test
the relative affinity of these selected peptides to MDA-
MB-435 cells. The selected peptides were manually
synthesized and labelled with FITC at the N-terminus via
a -alanine linker according to our previously reported
method (Scheme S1 in Supplementary Material) [30].
Our results illustrate that the order of fluorescence inten-
sity was as follows: peptide 19  > peptide 2 > peptide 3
when incubated with MDA-MB-435 cell lines. These
results indicate that peptides 2  and 19  have a higher bind-
ing affinity for the MDA-MB-435 cells compared to the
native p160 (peptide 3), which supports our finding from
the peptide array-cell binding assay.
The images obtained from the Elispot are very similar
to those obtained using the Kodak Imager. The foremost
concern that we see with the Elispot technique is that
the number that we obtained from the machine does not
reflect the number of spots that appear in each well. This
method is very good if we can obtain a reasonable num-
ber that reflects the binding affinity. The inability to use
the numbers obtained from the Elispot might be due to
the high concentration of peptide spots or high num-
ber of cells that are preincubated with the membrane; in
both cases, this results in a large number of cells bind-
ing to each spot. This drawback could be overcome by
reducing either the spot size, peptide concentration or
number of cells, which will result in enhancing com-
petition between different peptides. The peptide-arraythesis, and validation of an in vitro platform peptide-whole
), http://dx.doi.org/10.1016/j.jtusci.2016.10.001
whole cell binding assay could be very useful for testing
the particular type of binding affinity, especially if there
is a low level of expression of the specific antigen that we
seek. Nonetheless, this peptide scan approach is a fast,
ARTICLE IN PRESS+ModelJTUSCI-340; No. of Pages 10
8 S. Ahmed, K. Kaur / Journal of Taibah University for Science xxx (2016) xxx–xxx
Fig. 6. Binding affinity of the P160 peptide library to MDA-MB-435 and HUVEC cells. Top: optical density of the P160 peptide library as obtained
from the Kodak imager @535 nm. The results are presented as the mean optical density (OD) ± SD; the cellulose membrane and cells (75 × 103/mL)
were incubated with the peptide array for 8 h at 37 ◦C, which was followed by staining the cells with MTT reagent. Bottom: spotscan image after
incubation with MDA-MB-435 cell lines as taken using the Kodak imager.
 with 1Fig. 7. FACS analysis overlay for MDA-MB-435 cells after incubation
3, shaded) for 30 min at 37 ◦C.
relatively simple screening tool that can provide valuable
information on ligand–receptor interaction sites.
3.  ConclusionPlease cite this article in press as: S. Ahmed, K. Kaur. Design, syn
cell screening assay using MTT reagent, J. Taibah Univ. Sci. (2016
In summary, the results of our study showed that
covalently immobilized peptides demonstrate a valuable
tool for improving cancer targeting peptides. The colour0−6 mol/L of peptides (2(A) and 19(B), unshaded) with p160 (peptide
detection tool introduced in the current study enhances
the rapid evaluation of binding affinity to different cancer
tissues. Our results support previously obtained obser-
vations using fluorescence detection. Different peptidesthesis, and validation of an in vitro platform peptide-whole
), http://dx.doi.org/10.1016/j.jtusci.2016.10.001
identified here provide promising sequences with an
improved binding affinity of up to 3-fold, which is useful
for both identifying cancer targeting peptides and gener-
ating diagnostic tools for cancer. It is worth mentioning
 IN+ModelJ
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